Login to Your Account

Other News To Note

Tuesday, November 19, 2013

• Gilead Sciences Inc., of Foster City, Calif., said the European Commission granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor to treat HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription